When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

The clinical-stage biotech is developing gene-editing CRISPR technology. Editas has reported encouraging testing results in laboratory animals. Editas Medicine (NASDAQ: EDIT) is a promising ...

The average Wall Street analyst following Editas Medicine ( EDIT 7.08%) thinks the gene therapy stock can reach $3.25 per share in the next year. From recent prices, this implies a gain of about 53% ...

Researchers have successfully 3D printed insulin-producing human pancreas cells that could revolutionize treatment for Type 1 ...

A smart molecular tool developed by scientists can aid plants facing rising temperatures and infections.Plants often feel stressed, especially when the weather is extreme or microbes attack. When they ...

CRISPR systems in general act as "molecular scissors" by cutting DNA into pieces, be it in a lab-based setting or, in nature, inside a bacterium to destroy a phage. Imagine wanting to use a phage ...

Melbourne scientists have shown for the first time how a “revolutionary” blood cancer treatment could be tweaked to also cure ...

Gene editing techniques and maize genetic material may be the seed for more robust and stress tolerant canola plants. Canadian research is trying to make it happen.

Victoria Gray, the first person cured of sickle cell using CRISPR gene editing therapies, spoke in Fargo about her journey and the need to lower the $2M treatment cost.

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.